Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA

被引:81
作者
Schmued, LC [1 ]
机构
[1] US FDA, Natl Ctr Toxicol Res, Dept Neurotoxicol, Jefferson, AR 72079 USA
关键词
methylenedioxymethamphetamine; ecstasy; Fluoro-Jade B; pathology; neuronal degeneration;
D O I
10.1016/S0006-8993(03)02563-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Methylenedioxymethamphetamine (MDMA, Ecstasy) is a powerful releaser of serotonin. Increasing recreational use of this stimulant and hallucinogenic drug has raised concerns about its potential to produce brain damage. The vast majority of previous research studies have focused on the compound's ability to deplete serotonin (5-hydroxytryptamine, 5-HT) from axon terminals. Despite extensive research on this '5-HT terminal neurotoxicity', a much less studied aspect of MDMA toxicity involves its ability to actually kill nerve cells. Only two prior studies mention the existence of MDMA-induced neuronal degeneration, as reflected by a limited number of argyrophylic neurons within the somatosensory cortex, following very high doses of MDMA. The development of Fluoro-Jade B as a simple and reliable marker of neuronal degeneration has allowed us to conduct the first comprehensive localization of MDMA induced neuronal degeneration throughout the entire rat forebrain. In addition to the previously reported neuronal degeneration within parietal cortex, degenerating neurons were also observed in the insular/perirhinal cortex, the ventromedial/ventrolateral thalamus, and the tenia tecta. The extent of neuronal degeneration observed generally correlated with the degree of hyperthermia achieved. Published by Elsevier Science B.V.
引用
收藏
页码:127 / 133
页数:7
相关论文
共 31 条
[1]  
ALI SF, 1989, RES COMMUN SUBSTANCE, V10, P225
[2]  
BATTAGLIA G, 1987, J PHARMACOL EXP THER, V242, P911
[3]  
BROENING HW, 1995, J PHARMACOL EXP THER, V275, P325
[4]   ALPHA-METHYLTYROSINE BLOCKS METHYLAMPHETAMINE-INDUCED DEGENERATION IN THE RAT SOMATOSENSORY CORTEX [J].
COMMINS, DL ;
SEIDEN, LS .
BRAIN RESEARCH, 1986, 365 (01) :15-20
[5]  
COMMINS DL, 1987, J PHARMACOL EXP THER, V241, P338
[6]  
DUHAULT J, 1967, ARCH INT PHARMACOD T, V170, P276
[7]  
GAYLOR DW, 1990, NEUROTOXICOLOGY, V11, P211
[8]  
GREER G, 1985, AM J PSYCHIAT, V142, P1391
[9]  
HARMAN HF, 1973, TOXICOL APPL PHARM, V25, P299
[10]  
JENSEN KF, 1993, ASSESSING NEUROTOXIC, P133